mRNA-1388 / Moderna - LARVOL DELTA

Chikungunya vaccine development, challenges, and pathway toward public health impact. (PubMed, Vaccine) - "Five chikungunya vaccine candidates (BBV87 - BBIL/IVI, MV-CHIK - Themis Bioscience, ChAdOx1 Chik - University of Oxford, PXVX0317 / VRC-CHKVLP059-00-VP - Bavarian Nordic, and mRNA-1388 - Moderna) are in development...This could partly be facilitated through obtaining consensus on scientific and regulatory principles for initial vaccine introduction and generating evidence on chikungunya burden and disease awareness among populations at risk. Specifically, this article advocates for the formation of a global chikungunya vaccine consortium that includes regulators, policymakers, sponsors, and manufacturers to assist in overcoming the global and local challenges for chikungunya vaccine licensure, policy, financing, demand generation, and access to at-risk populations."

Journal • Review • Chikungunya • Infectious Disease

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis. (PubMed, Vaccines (Basel)) - "We performed a meta-analysis to estimate the immunogenicity and safety of all chikungunya vaccines that have been progressed to clinical trial evaluation (VLA1553; mRNA-1388/VAL-181388; PXVX0317/VRC-CHKVLP059-00-VP; ChAdOx1 Chik; MV-CHIK). Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations."

Journal • Retrospective data • Review • Chikungunya

A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. (PubMed, Vaccine) - P1 | "mRNA-1388, the first mRNA vaccine against CHIKV, was well tolerated and elicited substantial and long-lasting neutralizing antibody responses in healthy adult participants in a nonendemic region."

Journal • P1 data • Chikungunya • Infectious Disease

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: ModernaTX, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects (clinicaltrials.gov) - P1; N=60; Active, not recruiting; Sponsor: ModernaTX, Inc.; Trial completion date: Sep 2019 ➔ Dec 2019; Trial primary completion date: Sep 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects (clinicaltrials.gov) - P1; N=60; Active, not recruiting; Sponsor: ModernaTX, Inc.; Trial completion date: Mar 2019 ➔ Sep 2019; Trial primary completion date: Mar 2019 ➔ Sep 2019

Clinical • Trial completion date • Trial primary completion date